Swiss giant Novartis to buy US-based AveXis in $8.7B deal

Swiss giant Novartis to buy US-based AveXis in $8.7B deal



Swiss pharmaceuticals giant Novartis says it has agreed to buy the U.S.-based gene therapy company AveXis Inc. for $8.7 billion, part of its goal to become a leader in the treatment of neurodegenerative diseases.